Trial Profile
A Phase I Study of NK012 in Combination With Carboplatin in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Triple Negative Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs NK 012 (Primary) ; Carboplatin
- Indications Advanced breast cancer; Male breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Nippon Kayaku
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Nov 2010 New trial record